Research

We are proud of the effectiveness of the Nasaleze products and the positive impact they can make. To help demonstrate this efficacy, we have worked with Professors, Doctors, and Academics from around the globe to conduct over 40 trials. These have been published and presented all over the world.

These studies have reviewed the benefits that Nasaleze products can give to people suffering from allergic rhinitis, the impact on cold prevention, and the ability to protect against Human Coronavirus.

Dr Roger Henderson

Dr Roger Henderson, a Senior GP who has written multiple books and regularly appears on television and radio, has reviewed the supporting research.

"The research that’s been carried out shows that methyl-cellulose powder - the key ingredient in Nasaleze - has been shown to act as a significant barrier against cold viruses and inhaled allergens, such as pollens. It also shows the addition of powdered garlic extract in the Nasaleze Travel and the Nasaleze Cold & Flu Blocker sprays is highly significant in helping to prevent airborne infections whilst people are on the move.

There have been over thirty clinical studies looking at the effectiveness of methyl-cellulose powder in reducing nasal allergy symptoms, and almost the same number analysing its general benefits and safety. The level of research showing the benefits of Nasaleze is not only statistically significant but also backed up by the quality of the studies involved.

These extensive studies - along with the fact that Nasaleze is a drug-free product which can be safely used by everyone, including children and pregnant women - should give added confidence to anyone considering using it. Using Nasaleze regularly not only reduces the risk of catching a cold, but also significantly improves the quality of life of people suffering with allergy-triggered nasal symptoms."

Below is a selection of the research studies that have been conducted to prove the safety and efficacy of the Nasaleze product range. Here you can see a short overview of a few:

Nasaleze Allergy Blocker

  1. Clinical review paper; Methyl cellulose powder for the prevention and management of nasal symptoms, Popov T, Aberg N, Emberlin J, Josling P, Llyna NI, Nikitin NP, Church M. Published in Expert Review of Respiratory Medicine 11,11, 885-892 DOI 2017.
  2. Double blind placebo controlled cross over trial of inert cellulose powder, by nasal provocation with grass pollen to assess efficacy of the product in controlling symptoms of hay fever, Emberlin J and Lewis R, Poster presented at European Academy of Allergy and Clinical in 2006.
  3. Effect of micronized cellulose powder on the efficacy of topical oxymetazoline in allergic rhinitis, Valerieva A, Popov T, Staevska M, Kralimarkova T, Petkova E, Valerieva E, Mustakov T, Lazarova T, Dimitrov V and Church MK. Published in Allergy Asthma Proceedings. 2015; 36(1).
  4. A nasally applied cellulose powder in seasonal allergic rhinitis in adults with grass pollen allergy; a double blind placebo controlled study. Aberg, Ospanova, Nikitin, Emberlin and Dahl. Published in International Archives of Allergy and Immunology.2014; 163(1).

Nasaleze Children’s Allergy Blocker

  1. Measure of improvement in nasal muco-ciliary clearance and PNIFR (peak nasal inspiratory flow rate) in children with allergic rhinitis, Aivazis, Bourli, Maratou et al. Published in Nea Pediatrica Chronica. 2005; 5(2). Presented at the World Allergy Congress in 2005.
  2. Reduction in symptoms of seasonal allergic rhinitis (SAR). A double blind, placebo-controlled trial in children and adolescents. Conducted at the Queen Silvia Children’s Hospital, Gothenburg, Sweden. Published in Paediatric Allergy and Immunology, 2011; 22(1). Presented at the European Academy of Allergy and Clinical Immunology in 2010.

Nasaleze Travel and Nasaleze Cold & Flu Blocker

  1. Preventing airborne infections with an intra-nasal cellulose powder formulation, Hiltunen R, Josling PD, James MH. Published in Advances in Therapy. 2007; 24(5): p1146-1153.
  2. Use of Nasaleze Cold/Travel as prevention method for acute respiratory illnesses in paediatrics, Geppe NA, Farber IM, Kozhevnikova TN, Andriyanova EV. Published in Pharmateka, No: 14, 2010, p.60-65
  3. Virucidal activity of Nasaleze Cold/Travel in cell cultures infected with pathogenic avian flu virus (H5N1) conducted at the Ivanovsky State Scientific Research Institute of Virology at the Russian Academy of Medical Sciences, Moscow. Published in the European Journal for Nutraceutical Research March 24th 2010.
  4. Virucidal activity of Nasaleze Cold/Travel in cell cultures infected with human pathogenic corona virus 229E, Hunt N, Suleman L, Josling P, Popov T. Unpublished data on file.

Nasaleze PM Shield

  1. Nasaleze powder in vitro study of the absorption of PM2.5 particles. Josling P, Church M, Popov TA. Poster presented at The American Academy of Allergy, Asthma & Immunology.

In addition, Nasaleze has several academic institution formal and branded mentions, which include:

bsaci Taylor and Francis AAIR WAO AAAA Dovepress

"I have done three double-blind placebo controlled clinical trials with Nasaleze and know from these that it is effective in reducing symptoms and has no known side effects. I recommend using Nasaleze as it stops the pollen, spores and other airborne allergens reaching the reactive cells in the nose lining, and so reduces the symptoms of allergic rhinitis including hay fever."

Dr Jean Emberlin, Scientific Consultant, Formerly Scientific Director at Allergy UK and former Professor and Director at the National Pollen and Aerobiology Research Unit, University of Worcester